Emerging Respiratory Viruses: Challenges and Vaccine Strategies

Overview

Journal Clin Microbiol Rev

Publisher American Society for Microbiology

Specialty Microbiology

Date 2006 Oct 17

PMID 17041137

Citations 70

Authors

Laura Gillim-Ross

Kanta Subbarao

Affiliations

Soon will be listed here.

Abstract

The current threat of avian influenza to the human population, the potential for the reemergence of severe acute respiratory syndrome (SARS)-associated coronavirus, and the identification of multiple novel respiratory viruses underline the necessity for the development of therapeutic and preventive strategies to combat viral infection. Vaccine development is a key component in the prevention of widespread viral infection and in the reduction of morbidity and mortality associated with many viral infections. In this review we describe the different approaches currently being evaluated in the development of vaccines against SARS-associated coronavirus and avian influenza viruses and also highlight the many obstacles encountered in the development of these vaccines. Lessons learned from current vaccine studies, coupled with our increasing knowledge of the host and viral factors involved in viral pathogenesis, will help to increase the speed with which efficacious vaccines targeting newly emerging viral pathogens can be developed.

Citing Articles

Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions.

Hsiung K, Chiang H, Reinig S, Shih S Vaccines (Basel). 2025; 12(12.

PMID: 39772007 PMC: 11679499. DOI: 10.3390/vaccines12121345.

Combating Emerging Respiratory Viruses: Lessons and Future Antiviral Strategies.

Muthukutty P, MacDonald J, Yoo S Vaccines (Basel). 2024; 12(11).

PMID: 39591123 PMC: 11598775. DOI: 10.3390/vaccines12111220.

Multiplexed Antibody Sequencing and Profiling of the Human Hemagglutinin-specific Memory B Cell Response following Influenza Vaccination.

Raju N, Kramer K, Cavallaro M, Diotti R, Shiakolas A, Campos Mota Y J Immunol. 2024; 213(11):1605-1619.

PMID: 39441352 PMC: 11573632. DOI: 10.4049/jimmunol.2400326.

Identification of South African Plant-Based Bioactive Compounds as Potential Inhibitors against the SARS-CoV-2 Receptor.

Mkolo N, Naidoo C, Kadye R, Obi C, Iweriebor B, Olaokun O Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065672 PMC: 11279959. DOI: 10.3390/ph17070821.

Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness.

Chattopadhyay A, Kader Jailani A, Mandal B Vaccines (Basel). 2023; 11(8).

PMID: 37631915 PMC: 10458178. DOI: 10.3390/vaccines11081347.

References

Wang S, Chou T, Sakhatskyy P, Huang S, Lawrence J, Cao H . Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol. 2005; 79(3):1906-10. PMC: 544123. DOI: 10.1128/JVI.79.3.1906-1910.2005. View

Yuen K, Chan P, Peiris M, Tsang D, Que T, Shortridge K . Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet. 1998; 351(9101):467-71. DOI: 10.1016/s0140-6736(98)01182-9. View

Gaydos J, Hodder R, Top Jr F, Allen R, Soden V, Nowosiwsky T . Swine influenza A at Fort Dix, New Jersey (January-February 1976). II. Transmission and morbidity in units with cases. J Infect Dis. 1977; 136 Suppl:S363-8. DOI: 10.1093/infdis/136.supplement_3.s363. View

Zitzow L, Rowe T, Morken T, Shieh W, Zaki S, Katz J . Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J Virol. 2002; 76(9):4420-9. PMC: 155091. DOI: 10.1128/jvi.76.9.4420-4429.2002. View

Chiu S, Chan K, Chu K, Kwan S, Guan Y, Poon L . Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China. Clin Infect Dis. 2005; 40(12):1721-9. PMC: 7107956. DOI: 10.1086/430301. View

Stadler K, Masignani V, Eickmann M, Becker S, Abrignani S, Klenk H . SARS--beginning to understand a new virus. Nat Rev Microbiol. 2004; 1(3):209-18. PMC: 7097337. DOI: 10.1038/nrmicro775. View

Kuiken T, Fouchier R, Schutten M, Rimmelzwaan G, van Amerongen G, van Riel D . Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet. 2003; 362(9380):263-70. PMC: 7112434. DOI: 10.1016/S0140-6736(03)13967-0. View

Couch R, KASEL J . Immunity to influenza in man. Annu Rev Microbiol. 1983; 37:529-49. DOI: 10.1146/annurev.mi.37.100183.002525. View

Kawaoka Y, Webster R . Sequence requirements for cleavage activation of influenza virus hemagglutinin expressed in mammalian cells. Proc Natl Acad Sci U S A. 1988; 85(2):324-8. PMC: 279540. DOI: 10.1073/pnas.85.2.324. View

10.

Cheung C, Poon L, Lau A, Luk W, Lau Y, Shortridge K . Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?. Lancet. 2002; 360(9348):1831-7. DOI: 10.1016/s0140-6736(02)11772-7. View

11.

Ksiazek T, Erdman D, Goldsmith C, Zaki S, Peret T, Emery S . A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003; 348(20):1953-66. DOI: 10.1056/NEJMoa030781. View

12.

Jin H, Lu B, Zhou H, Ma C, Zhao J, Yang C . Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology. 2003; 306(1):18-24. DOI: 10.1016/s0042-6822(02)00035-1. View

13.

Takasuka N, Fujii H, Takahashi Y, Kasai M, Morikawa S, Itamura S . A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol. 2004; 16(10):1423-30. PMC: 7108621. DOI: 10.1093/intimm/dxh143. View

14.

Govorkova E, Rehg J, Krauss S, Yen H, Guan Y, Peiris M . Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol. 2005; 79(4):2191-8. PMC: 546577. DOI: 10.1128/JVI.79.4.2191-2198.2005. View

15.

Dacso C, Couch R, Six H, Young J, Quarles J, KASEL J . Sporadic occurrence of zoonotic swine influenza virus infections. J Clin Microbiol. 1984; 20(4):833-5. PMC: 271447. DOI: 10.1128/jcm.20.4.833-835.1984. View

16.

SNYDER M, Betts R, DeBorde D, Tierney E, Clements M, Herrington D . Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J Virol. 1988; 62(2):488-95. PMC: 250559. DOI: 10.1128/JVI.62.2.488-495.1988. View

17.

Bukreyev A, Lamirande E, Buchholz U, Vogel L, Elkins W, St Claire M . Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet. 2004; 363(9427):2122-7. PMC: 7112367. DOI: 10.1016/S0140-6736(04)16501-X. View

18.

Peiris M, Yuen K, Leung C, Chan K, Ip P, Lai R . Human infection with influenza H9N2. Lancet. 1999; 354(9182):916-7. DOI: 10.1016/s0140-6736(99)03311-5. View

19.

Greenough T, Carville A, Coderre J, Somasundaran M, Sullivan J, Luzuriaga K . Pneumonitis and multi-organ system disease in common marmosets (Callithrix jacchus) infected with the severe acute respiratory syndrome-associated coronavirus. Am J Pathol. 2005; 167(2):455-63. PMC: 1603565. DOI: 10.1016/S0002-9440(10)62989-6. View

20.

Delmas B, Gelfi J, LHaridon R, Vogel L, Sjostrom H, Noren O . Aminopeptidase N is a major receptor for the entero-pathogenic coronavirus TGEV. Nature. 1992; 357(6377):417-20. PMC: 7095137. DOI: 10.1038/357417a0. View